This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Dentistry/ Oral Medicine  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic

Drugs May Have Niche in Prevention and Treatment

Tracy Hampton, PhD

JAMA. 2005;293:2579-2580.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Some nonsteroidal anti-inflammatory drugs (NSAIDs) have come under fire recently because of their link to increased risk of myocardial infarction and stroke. But increasing evidence suggests the value of some of these drugs for certain cancer patients may outweigh such risks, according to findings presented at the annual meeting of the American Association for Cancer Research, held in Anaheim in April.

ALTERED GENE SIGNATURE

One new study highlighted at the conference revealed the effects of the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib on gene expression in the colon of individuals genetically at risk for hereditary nonpolyposis colon cancer. Previously reported epidemiological studies have shown that COX-2 inhibitors suppress colorectal carcinogenesis and reduce the risk of death from colorectal cancer, and these new results may point to the mechanisms by which this is accomplished.

A new study found that long-term daily NSAID use reduced the risk of oral cancer in some smokers but . . . [Full Text of this Article]